Kudevita

General characteristics. Structure:

1 capsule contains OLL-Kew (Coenzyme Q10) of 10% of TG/P (structure of a semi-finished product: убидекаренон (coenzyme Q10) of 30 mg, triglycerides of fatty acids with an average length of chain of 7,2 mg, gelatin of 143,1 mg, sucrose of 47,7 mg,
starch of corn 72,0 mg) - 300,0 mg, silicon dioxide of colloid 6,0 mg; solid gelatin capsules No. 1 (capsule body composition: titanium dioxide of 2%, ferrous oxide of yellow 0,6286%, gelatin to 100%; structure of a cover of the capsule: titanium dioxide of 1%, ferrous oxide of yellow 0,6286%, gelatin to 100%).
Description. Capsules No. 1 of yellow color. Contents of capsules – powder light-orange color.

Pharmacological properties:

Pharmacodynamics. Ubidekarenon (coenzyme Q10, убихинон) – the natural substance which is a vitaminopodobny coenzyme. Ubidekarenon is endogenous substrate, takes part in transfer of electrons in a transport chain of oxidation-reduction processes, in the course of energy exchange, in reaction of oxidizing phosphorylation in a respiratory chain of mitochondrions of cells. Participates in processes of cellular respiration due to increase in synthesis of adenosine triphosphoric acid. Has clinically significant antioxidant effect. Protects lipids of cellular membranes from peroxide oxidation, preventing education of free radicals, thereby slowing down aging process. Reduces a zone of injury of a myocardium in the conditions of ischemia and reperfusion. Ubidekarenon does not extend QT an interval, improves portability of an exercise stress. Due to endogenous synthesis of 100% the satisfaction of need of an organism for coenzyme Q10 occurs only to 20-year age. Concentration of coenzyme Q10 decreases at patients of advanced age, and also at various diseases both at adults, and at children.

Pharmacokinetics. The maximum concentration averages 0,7 mkg/ml after intake of a dose of 120 mg. Time of achievement of the maximum concentration in a blood plasma - after intake the Elimination half-life makes 7 hours 3,5 hours. At prolonged use (from 4th to 12 weeks) kumulirut, generally in a liver and heart.

Indications to use:

Prevention and as a part of complex therapy of various diseases of cardiovascular system:
• Coronary heart disease, chronic heart failure (the II-III functional class on NYHA classification);
• Arterial hypertension;
• A myocardial infarction (during recovery therapy);
• The period of preparation for carrying out operations on heart (aortocoronary shunting, at heart diseases).
Prevention and as a part of complex therapy of migraine. For prevention and completion of insufficiency of coenzyme Q10. For improvement of adaptation to the raised exercise stresses at athletes.

Route of administration and doses:

For the purpose of prevention to accept on all adults and children declared to indications 12 years on 30 mg (1 capsule) a day after food in the first half of day are more senior. As a part of complex therapy at treatment of chronic heart failure and coronary heart disease appoint 150 mg (5 capsules) divided into 3-5 receptions a day after food. In complex therapy of arterial hypertension, myocardial infarction (during recovery therapy), during preparation for carrying out operations on heart (aortocoronary shunting, at heart diseases), migraines, for completion of insufficiency of coenzyme Q10 and improvement of adaptation to the raised exercise stresses at athletes, to adults and children are more senior than 12 years appoint from 30 mg (1 capsule) to 90 mg (3 capsules) a day. Duration of a course of use of drug makes 1-3 months. Increase in duration of a course of therapy and repeated courses – according to the recommendation of the doctor.

Side effects:

Allergic reactions (skin rash, itch), nausea, diarrhea, heartburn, pain in epigastriums are possible. If any of the side effects specified in the instruction are aggravated, or you noticed any other side effects which are not specified in the instruction, report about it to the doctor.

Interaction with other medicines:

Simultaneous use of hypolipidemic means (statines, fibrata), warfarin, the beta of adrenoblockers (атенолол, метопролол, propranolol), tricyclic antidepressants, can lead to decrease in concentration of an ubidekarenon in a blood plasma. Ubidekarenon can strengthen effect of diltiazem, a metoprolol, enalapril and nitrates.

Contraindications:

• hypersensitivity to drug components;
• acute glomerulonephritis;
• a peptic ulcer of a stomach and duodenum (in an aggravation stage);
• the expressed bradycardia (heart rate less than 50 beats/min);
• age up to 12 years;
• intolerance of fructose and syndrome of disturbance of absorption of a glucose/galactose or deficit of invertase/isomaltase. If at you one of the listed diseases, before administration of drug surely consult with the doctor.
With care
Arterial hypotension. And during feeding by a breast Drug are not recommended to appoint use at pregnancy pregnant women and the feeding women due to the lack of sufficient experience of a clinical use.

Overdose:

Data on overdose are absent.

Storage conditions:

In the dry place protected from light at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity 2 years. Not to use after the termination of a period of validity.

Issue conditions:

According to the recipe

Packaging:

Capsules of 30 mg. On 10 or 15 capsules in a blister strip packaging. On 100 capsules in bank polymeric with a cover. To bank, 3 or 6 blister strip packagings on 10 capsules, 2 or 4 blister strip packagings on 15 capsules together with the application instruction place in a pack from a cardboard.